Teva Pharmaceutical Industries TEVA
NYSE TEVA
$37.00 -0.48 (-1.28%)
At close: Aug 20, 2026 · 9:55 AM UTC

Teva Pharmaceutical Industries (TEVA) Restructuring Costs (2009 - 2013)

Teva Pharmaceutical Industries' (TEVA) quarterly Restructuring Costs came in at $47.0 million in Q3 2013, down 93.18% YoY from $689.0 million in Q3 2012, and down 96.72% on a QoQ basis from $1.4 billion in Q2 2013.

Teva Pharmaceutical Industries (TEVA) Restructuring Costs (2009 - 2013) Analysis & Trends

Teva Pharmaceutical Industries (TEVA) has 4 years of Restructuring Costs data on file, last reported at $47.0 million in Q3 2013.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 43.87 Bn 42.91 Bn -
2 Teva Pharmaceutical Industries 43.30 Bn 39.64 Bn 2.15 Bn
3 Zoetis 31.74 Bn 30.06 Bn 1.05 Bn
4 Takeda Pharmaceutical 28.74 Bn 22.95 Bn 5.10 Bn
5 United Therapeutics 22.26 Bn 19.60 Bn 683.80 Mn
6 Viatris 18.85 Bn 17.96 Bn 1.46 Bn
7 Neurocrine Biosciences 15.67 Bn 15.28 Bn 935.80 Mn
8 Elanco Animal Health 12.15 Bn 11.62 Bn 798.00 Mn
9 Dr Reddys Laboratories 10.13 Bn 9.96 Bn -
10 Alkermes 8.28 Bn 7.62 Bn 397.90 Mn

Historic Data

Download Data
DateValue
Sep 30, 2013 47.00 Mn
Jun 30, 2013 1.44 Bn
Mar 31, 2013 41.00 Mn
Sep 30, 2012 689.00 Mn
Jun 30, 2012 21.00 Mn
Mar 31, 2012 40.00 Mn
Sep 30, 2011 36.00 Mn
Sep 30, 2009 97.00 Mn
Jun 30, 2009 52.00 Mn
Mar 31, 2009 14.00 Mn